年龄对局限期胰腺癌生活质量、90天死亡率、辅助化疗及生存的影响:全国性分析
这项全国性队列研究(2015-2023)纳入5217例局限期胰腺癌患者,比较≥75岁与<75岁患者接受切除、单纯化疗或立体定向放疗后的健康相关生活质量、90天死亡率、辅助化疗使用及总生存。结果显示老年患者纵向生活质量与年轻患者相当,但90天术后死亡率更高且辅助化疗使用更少,年龄并非总生存的独立影响因素。
要点
- 老年与年轻局限期胰腺癌患者的纵向健康相关生活质量总体相当。
- 老年患者90天术后死亡率更高(调整OR 1.6,95%CI 1.2-2.23,P=0.003)。
- 老年患者接受辅助化疗的可能性更低(调整OR 0.4,95%CI 0.3-0.4,P<0.001),但年龄非总生存独立影响因素。
核心结论
- 老年患者报告的纵向健康相关生活质量与年轻患者相当。
- 较高年龄与更高的90天死亡率和更少的辅助化疗使用相关,但与总生存无独立关联。
- 这些发现支持个体化共享决策,并提示不应仅因年龄而排除治疗。
研究设计与样本
- 全国性队列研究,纳入2015-2023年局限期胰腺癌患者(可切除、交界可切除和局部晚期)。
- 共纳入5217例患者,其中手术切除3496例、单纯化疗1459例、立体定向体部放疗262例。
- 按年龄分为老年组(≥75岁)和年轻组(<75岁)。
- 主要结局为采用EORTC QLQ-C30评估的健康相关生活质量;次要结局包括总生存、90天死亡率和辅助化疗。
主要发现
- 手术后,老年患者在0-3个月报告呼吸困难较少,但在9-12个月角色功能更差、疲劳和疼痛更多。
- 单纯化疗患者中,老年与年轻患者之间未观察到差异。
- 老年患者90天术后死亡率更高(调整OR:1.6,95%CI[1.2-2.23],p=0.003)。
- 老年患者接受辅助化疗的可能性更低(调整OR:0.4,95%CI[0.3-0.4],p<0.001)。
- 年龄在各治疗组中均不是总生存的独立相关因素。
关键数值与推荐
- 健康相关生活质量采用EORTC QLQ-C30评估,线性混合模型分析,Bonferroni校正后p<0.013为显著。
- 90天死亡率和辅助化疗采用逻辑回归分析。
- 总生存采用Cox比例风险模型分析。
临床怎么用
- 对老年局限期胰腺癌患者,不应仅因年龄而排除手术、化疗或放疗等治疗选择。
- 应关注老年患者术后90天死亡风险升高及辅助化疗使用减少的情况,结合个体化评估进行共享决策。
- 老年患者术后9-12个月可能出现角色功能下降、疲劳和疼痛加重,需加强相应支持管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pancreatic cancer has a poor prognosis. Multiple treatment modalities are available, their impact on health-related quality of life (HRQoL) and overall survival (OS) in older patients remains unclear. This study compared HRQoL, postoperative mortality, adjuvant chemotherapy use and OS after various treatment strategies between elderly and younger patients with localized pancreatic cancer. METHODS: In this nationwide cohort study (2015-2023), patients with localized pancreatic cancer (resectable, borderline resectable and locally advanced disease) treated with surgical resection, chemotherapy alone, or stereotactic body radiation therapy (SBRT) were included and stratified into elderly (≥75years) and younger (<75years). The primary outcome was HRQoL assessed with the EORTC QLQ-C30. Secondary outcomes included OS, 90-day mortality, and adjuvant chemotherapy. Linear mixed models with Bonferroni correction (p < 0.013) evaluated HRQoL. Logistic regression assessed 90-day mortality and adjuvant chemotherapy. OS was analyzed using Cox proportional hazards models. RESULTS: 5217 patients were included (3496 resection, 1459 chemotherapy-only, and 262 SBRT). Following resection, elderly reported less dyspnea at 0-3 months but worse role functioning, more fatigue and pain at 9-12 months. No differences were observed between patients treated with chemotherapy only. Elderly patients had higher 90-day postoperative mortality (adjusted OR:1.6, 95%CI[1.2-2.23],p = 0.003) and were less likely to receive adjuvant chemotherapy (adjusted OR:0.4, 95%CI[0.3-0.4],p < 0.001). Age was not independently associated with OS across treatment groups. CONCLUSION: Elderly patients reported comparable longitudinal HRQoL as to younger patients. Higher age was associated with higher 90-day mortality and less use of adjuvant chemotherapy, but it was not independently associated with overall survival. These findings support individualized shared decision-making and suggest that age alone should not preclude treatment.
引用
- Scheepens JCM, Prinsze KJ, van Geest LG, et al. The impact of age on quality of life, 90-day mortality, adjuvant chemotherapy, and survival after treatment for localized pancreatic cancer: A nationwide analysis. Eur J Cancer. 2026. PMID: 42208281. doi:10.1016/j.ejca.2026.116822
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。